EA026384B1 - Лечение заболеваний сердца - Google Patents

Лечение заболеваний сердца Download PDF

Info

Publication number
EA026384B1
EA026384B1 EA201290540A EA201290540A EA026384B1 EA 026384 B1 EA026384 B1 EA 026384B1 EA 201290540 A EA201290540 A EA 201290540A EA 201290540 A EA201290540 A EA 201290540A EA 026384 B1 EA026384 B1 EA 026384B1
Authority
EA
Eurasian Patent Office
Prior art keywords
agd
azr
compound
zeg
tug
Prior art date
Application number
EA201290540A
Other languages
English (en)
Russian (ru)
Other versions
EA201290540A1 (ru
Inventor
Йорген Соберг Петерсен
Анна Луиза Кьёлби
Мари Сковгаард
Хенрик Дьюлунд Педерсен
Лене Аксельсен
Дитте Рибер
Эдди Мейер
Рие Шультц Хансен
Келд Фосгерау
Бьярне Дью Ларсен
Original Assignee
Зилэнд Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA026384(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зилэнд Фарма А/С filed Critical Зилэнд Фарма А/С
Publication of EA201290540A1 publication Critical patent/EA201290540A1/ru
Publication of EA026384B1 publication Critical patent/EA026384B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EA201290540A 2010-01-20 2011-01-20 Лечение заболеваний сердца EA026384B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Publications (2)

Publication Number Publication Date
EA201290540A1 EA201290540A1 (ru) 2013-03-29
EA026384B1 true EA026384B1 (ru) 2017-04-28

Family

ID=43928934

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290540A EA026384B1 (ru) 2010-01-20 2011-01-20 Лечение заболеваний сердца

Country Status (15)

Country Link
US (1) US20130157953A1 (enExample)
EP (1) EP2525809B1 (enExample)
JP (2) JP2013517307A (enExample)
KR (1) KR20120128129A (enExample)
CN (1) CN102892425A (enExample)
AU (1) AU2011206979B2 (enExample)
BR (1) BR112012018104A2 (enExample)
CA (1) CA2786934A1 (enExample)
CL (1) CL2012002037A1 (enExample)
EA (1) EA026384B1 (enExample)
IL (1) IL220876A0 (enExample)
MX (1) MX342409B (enExample)
NZ (1) NZ601167A (enExample)
PH (1) PH12012501494A1 (enExample)
WO (1) WO2011088837A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2502218T3 (es) 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
AR081975A1 (es) * 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
CA2802897A1 (en) * 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
KR20140114845A (ko) * 2011-12-23 2014-09-29 질랜드 파마 에이/에스 글루카곤 유사체
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014081872A1 (en) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
US20150344540A1 (en) * 2012-12-19 2015-12-03 Novo Nordisk A/S Novel glp-1 receptor agonists with cholesterol efflux activity
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
AR098065A1 (es) * 2013-10-17 2016-04-27 Zealand Pharma As Análogos de glucagón acilados
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) * 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP2017536343A (ja) * 2014-10-10 2017-12-07 ノヴォ ノルディスク アー／エス 安定したｇｌｐ−１ベースのｇｌｐ−１／グルカゴン受容体コアゴニスト
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
KR102291020B1 (ko) * 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
FI3322437T3 (fi) 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
JP6712323B2 (ja) 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
GB2566228A (en) 2016-06-09 2019-03-06 AmideBio LLC Glucagon analogs and methods of use thereof
CN122440793A (zh) 2016-06-29 2026-07-24 韩美药品株式会社 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
CN115304666B (zh) * 2017-11-24 2025-09-19 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
CN109836503B (zh) * 2017-11-24 2022-09-16 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AU2019205905B2 (en) 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
KR102886870B1 (ko) * 2020-05-09 2025-11-18 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
EP1421950A1 (en) * 2002-11-19 2004-05-26 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040788A1 (en) * 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
EP2471810A1 (en) 2006-02-22 2012-07-04 Merck Sharp & Dohme Corporation Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
NZ578948A (en) * 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CA2728284C (en) * 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
WO2010107487A2 (en) * 2009-03-18 2010-09-23 Wu Nian Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO2002034285A2 (en) * 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
EP1421950A1 (en) * 2002-11-19 2004-05-26 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
WO2008152403A1 (en) * 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GILLIAN L. SOWDEN, DANIEL J. DRUCKER, DAVID WEINSHENKER, STEVEN J. SWOAP: "Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor", AMERICAN JOURNAL OF PHYSIOLOGY: REGULATORY, INTEGRATIVE AND COMPARATIVE PHYSIOLOGY., AMERICAN PHYSIOLOGICAL SOCIETY., US, vol. 292, no. 2, 1 February 2007 (2007-02-01), US, pages R962 - R970, XP002637634, ISSN: 0363-6119, DOI: 10.1152/ajpregu.00405.2006 *
GRIEVE D J, CASSIDY R S, GREEN B D: "Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: Potential therapeutic benefits beyond glycaemic control?", BRITISH JOURNAL OF PHARMACOLOGY, WILEY-BLACKWELL, UK, vol. 157, no. 8, 1 January 2009 (2009-01-01), UK, pages 1340 - 1351, XP002637632, ISSN: 0007-1188, DOI: 10.1111/J.1476-5381.2009.00376.X *
MAYER S E, NAMM D H, RICE L R: "EFFECT OF GLUCAGON ON CYCLIC 3 5 AMP PHOSPHORYLASE ACTIVITY AND CONTRACTILITY OF HEART MUSCLE OF THE RAT", CIRCULATION RESEARCH., GRUNE AND STRATTON, BALTIMORE, US, vol. 26, no. 2, 1 January 1970 (1970-01-01), US, pages 225 - 233, XP002637631, ISSN: 0009-7330 *
ROBBERECHT, P. ; WAELBROECK, M. ; CAMUS, J.-C. ; DE NEEF, P. ; COY, D.H. ; CHRISTOPHE, J.: "Comparative efficacy of seven synthetic glucagon analogs, modified in position 1, 2 and/or 12, on liver and heart adenylate cyclase from rat", PEPTIDES, ELSEVIER, AMSTERDAM, NL, vol. 7, 1 January 1986 (1986-01-01), AMSTERDAM, NL, pages 109 - 112, XP023486854, ISSN: 0196-9781, DOI: 10.1016/0196-9781(86)90172-5 *
SARACENI CHRISTINE; BRODERICK TOM L: "Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function.", DRUGS IN R & D, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 8, no. 3, 1 January 2007 (2007-01-01), NZ, pages 145 - 153, XP009095298, ISSN: 1174-5886, DOI: 10.2165/00126839-200708030-00002 *
UESAKA TOSHIHIRO, ET AL: "Glucagon-like peptide isolated from the eel intestine: Effects on atrial beating", JOURNAL OF EXPERIMENTAL BIOLOGY., COMPANY OF BIOLOGISTS, CAMBRIDGE, GB, vol. 204, no. 17, 1 September 2001 (2001-09-01), GB, pages 3019 - 3026, XP002637633, ISSN: 0022-0949 *

Also Published As

Publication number Publication date
JP2013517307A (ja) 2013-05-16
AU2011206979A1 (en) 2012-08-02
US20130157953A1 (en) 2013-06-20
BR112012018104A2 (pt) 2017-10-17
IL220876A0 (en) 2012-09-24
JP6200025B2 (ja) 2017-09-20
EA201290540A1 (ru) 2013-03-29
AU2011206979B2 (en) 2015-09-10
CL2012002037A1 (es) 2012-09-07
EP2525809B1 (en) 2016-08-03
PH12012501494A1 (en) 2012-10-22
CA2786934A1 (en) 2011-07-28
WO2011088837A1 (en) 2011-07-28
MX342409B (es) 2016-09-28
KR20120128129A (ko) 2012-11-26
NZ601167A (en) 2014-12-24
JP2016138127A (ja) 2016-08-04
EP2525809A1 (en) 2012-11-28
MX2012008440A (es) 2012-08-15
CN102892425A (zh) 2013-01-23

Similar Documents

Publication Publication Date Title
AU2011206979B2 (en) Treatment of cardiac conditions
US9403894B2 (en) Glucagon analogues
US8642540B2 (en) Glucagon analogues
US8642541B2 (en) Glucagon analogues
US8680049B2 (en) Glucagon analogues
EA020537B1 (ru) Аналоги глюкагона
CN104144696A (zh) 胰高血糖素类似物
WO2011020319A1 (zh) 调节血糖血脂的融合蛋白及其制备方法和应用
TW202604565A (zh) 用於預防或治療心血管疾病之三重ｇｌｐ－１／ｇｉｐ／升糖素受體促效劑及包含該促效劑之醫藥組成物
JP6006264B2 (ja) グルカゴン類似体
JP5912150B2 (ja) グルカゴン類似体
JP2014210799A (ja) グルカゴン類似体
OA16287A (en) Glucagon analogues.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM